Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer

Toxicity-related dose reduction is a common event in mRCC patients who have started first-line therapy with either sunitinib or pazopanib. This is positively related to the outcomes of both first- and second-line therapy.